Detalhe da pesquisa
1.
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Lancet
; 403(10426): 533-544, 2024 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38310910
2.
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
Lancet
; 397(10287): 1809-1818, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33964223
3.
Mass administration of azithromycin reduces childhood mortality in Niger.
Arch Dis Child Educ Pract Ed
; 106(5): 320, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900778
4.
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Lancet Infect Dis
; 24(5): 465-475, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342107
5.
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria.
Front Immunol
; 13: 795463, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35197971
6.
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Lancet Infect Dis
; 22(12): 1728-1736, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087586